Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of… Read more
Medexus Pharmaceuticals Inc (MEDXF) - Total Liabilities
Latest total liabilities as of September 2025: $97.02 Million USD
Based on the latest financial reports, Medexus Pharmaceuticals Inc (MEDXF) has total liabilities worth $97.02 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Medexus Pharmaceuticals Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Medexus Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Medexus Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Medexus Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IF Bancorp Inc
NASDAQ:IROQ
|
USA | $743.01 Million |
|
Sambo Motors Co. Ltd
KQ:053700
|
Korea | ₩856.71 Billion |
|
Multitude SE
LSE:0R4W
|
UK | €820.06 Million |
|
Talenom Oyj
HE:TNOM
|
Finland | €129.23 Million |
|
Asian Alliance International PCL
BK:AAI
|
Thailand | ฿768.97 Million |
|
Graha Andrasentra Propertindo Tbk PT
JK:JGLE
|
Indonesia | Rp439.35 Billion |
|
Butler National Corp
OTCQX:BUKS
|
USA | $57.97 Million |
|
Homerun Resources Inc.
PINK:HMRFF
|
USA | $1.70 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Medexus Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medexus Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medexus Pharmaceuticals Inc (2017–2025)
The table below shows the annual total liabilities of Medexus Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $119.69 Million | -4.56% |
| 2024-03-31 | $125.41 Million | -9.70% |
| 2023-03-31 | $138.88 Million | +14.37% |
| 2022-03-31 | $121.43 Million | -6.94% |
| 2021-03-31 | $130.50 Million | -6.61% |
| 2020-03-31 | $139.74 Million | +83.17% |
| 2019-03-31 | $76.29 Million | +1126.56% |
| 2018-03-31 | $6.22 Million | -3.30% |
| 2017-03-31 | $6.43 Million | -- |